# Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

> **NCT00130897** · — · APPROVED_FOR_MARKETING · sponsor: **Pfizer**

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sutent

## Key facts

- **NCT ID:** NCT00130897
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** 2005-07
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** — (—)
- **Last updated:** 2012-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130897, "Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00130897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*